Skip to content

The application of nalbuphine combined with propofol in painless gastroscopy.

The application of nalbuphine combined with propofol in painless gastroscopy.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099837
Enrollment
Unknown
Registered
2025-03-31
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastroscopy

Interventions

Experimental group:Propofol at 2 mg/kg, with an initial dose of Nalbuphine at 0.1 mg/kg, adjusted in increments of 0.01 mg/kg using the Dixon up-and-down method

Sponsors

The Third People's Hospital of Hefei City
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients scheduled for painless gastrointestinal endoscopy, aged 18-65 years, with a BMI of 18-28 kg/m^2, and ASA physical status I-II.

Exclusion criteria

Exclusion criteria: Allergy to nalbuphine or propofol; liver or kidney dysfunction; history of neurologic, respiratory or cardiovascular disorders; psychiatric illness

Design outcomes

Primary

MeasureTime frame
Dose of nalbuphine(mg);Total dose of propofol(mg);Ramsay Sedation Scale (RSS) score;

Secondary

MeasureTime frame
Awakening time(s);Adverse events;

Countries

China

Contacts

Public ContactJiang Meng

The Third People's Hospital of Hefei City

13739270811@163.com+86 137 3927 0811

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026